Cargando…

The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients

Gut microbiota plays an essential role in the development of rheumatoid arthritis (RA) and affects drug responses. However, the underlying mechanism remains elusive and urgent to elucidate to explore the pathology and clinical treatment of RA. Therefore, we selected methotrexate (MTX) as an example...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Maozhen, Zhang, Na, Mao, Yujie, Huang, Bingbing, Ren, Mengfei, Peng, Zhangjie, Bai, Zipeng, Chen, Long, Liu, Yan, Wang, Shanshan, Huang, Shenghai, Cheng, Zhixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024311/
https://www.ncbi.nlm.nih.gov/pubmed/35464950
http://dx.doi.org/10.3389/fmicb.2022.839015
_version_ 1784690550781247488
author Han, Maozhen
Zhang, Na
Mao, Yujie
Huang, Bingbing
Ren, Mengfei
Peng, Zhangjie
Bai, Zipeng
Chen, Long
Liu, Yan
Wang, Shanshan
Huang, Shenghai
Cheng, Zhixiang
author_facet Han, Maozhen
Zhang, Na
Mao, Yujie
Huang, Bingbing
Ren, Mengfei
Peng, Zhangjie
Bai, Zipeng
Chen, Long
Liu, Yan
Wang, Shanshan
Huang, Shenghai
Cheng, Zhixiang
author_sort Han, Maozhen
collection PubMed
description Gut microbiota plays an essential role in the development of rheumatoid arthritis (RA) and affects drug responses. However, the underlying mechanism remains elusive and urgent to elucidate to explore the pathology and clinical treatment of RA. Therefore, we selected methotrexate (MTX) as an example of RA drugs to explore the interactions between the gut microbiota and drug responses and obtain an in-depth understanding of their correlation from the perspective of the metabolic capability of gut microbiota on drug metabolism. We identified 2,654 proteins and the corresponding genes involved in MTX metabolism and then profiled their abundances in the gut microbiome datasets of four cohorts. We found that the gut microbiota harbored various genes involved in MTX metabolism in healthy individuals and RA patients. Interestingly, the number of genes involved in MTX metabolism was not significantly different between response (R) and non-response (NR) groups to MTX, but the gene composition in the microbial communities significantly differed between these two groups. Particularly, several models were built based on clinical information, as well as data on the gene, taxonomical, and functional biomarkers by using the random forest algorithm and then validated. Our findings provide bases for clinical management not only of RA but also other gut microbiome–related diseases. First, it suggests that the potential metabolic capability of gut microbiota on drug metabolism is important because they affect drug efficiency; as such, clinical treatment strategies should incorporate the gene compositions of gut microbial communities, in particular genes involved in drug metabolism. Second, a suitable model can be developed to determine hosts’ responses to drugs before clinical treatment.
format Online
Article
Text
id pubmed-9024311
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90243112022-04-23 The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients Han, Maozhen Zhang, Na Mao, Yujie Huang, Bingbing Ren, Mengfei Peng, Zhangjie Bai, Zipeng Chen, Long Liu, Yan Wang, Shanshan Huang, Shenghai Cheng, Zhixiang Front Microbiol Microbiology Gut microbiota plays an essential role in the development of rheumatoid arthritis (RA) and affects drug responses. However, the underlying mechanism remains elusive and urgent to elucidate to explore the pathology and clinical treatment of RA. Therefore, we selected methotrexate (MTX) as an example of RA drugs to explore the interactions between the gut microbiota and drug responses and obtain an in-depth understanding of their correlation from the perspective of the metabolic capability of gut microbiota on drug metabolism. We identified 2,654 proteins and the corresponding genes involved in MTX metabolism and then profiled their abundances in the gut microbiome datasets of four cohorts. We found that the gut microbiota harbored various genes involved in MTX metabolism in healthy individuals and RA patients. Interestingly, the number of genes involved in MTX metabolism was not significantly different between response (R) and non-response (NR) groups to MTX, but the gene composition in the microbial communities significantly differed between these two groups. Particularly, several models were built based on clinical information, as well as data on the gene, taxonomical, and functional biomarkers by using the random forest algorithm and then validated. Our findings provide bases for clinical management not only of RA but also other gut microbiome–related diseases. First, it suggests that the potential metabolic capability of gut microbiota on drug metabolism is important because they affect drug efficiency; as such, clinical treatment strategies should incorporate the gene compositions of gut microbial communities, in particular genes involved in drug metabolism. Second, a suitable model can be developed to determine hosts’ responses to drugs before clinical treatment. Frontiers Media S.A. 2022-04-08 /pmc/articles/PMC9024311/ /pubmed/35464950 http://dx.doi.org/10.3389/fmicb.2022.839015 Text en Copyright © 2022 Han, Zhang, Mao, Huang, Ren, Peng, Bai, Chen, Liu, Wang, Huang and Cheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Han, Maozhen
Zhang, Na
Mao, Yujie
Huang, Bingbing
Ren, Mengfei
Peng, Zhangjie
Bai, Zipeng
Chen, Long
Liu, Yan
Wang, Shanshan
Huang, Shenghai
Cheng, Zhixiang
The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients
title The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients
title_full The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients
title_fullStr The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients
title_full_unstemmed The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients
title_short The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients
title_sort potential of gut microbiota metabolic capability to detect drug response in rheumatoid arthritis patients
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024311/
https://www.ncbi.nlm.nih.gov/pubmed/35464950
http://dx.doi.org/10.3389/fmicb.2022.839015
work_keys_str_mv AT hanmaozhen thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT zhangna thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT maoyujie thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT huangbingbing thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT renmengfei thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT pengzhangjie thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT baizipeng thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT chenlong thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT liuyan thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT wangshanshan thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT huangshenghai thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT chengzhixiang thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT hanmaozhen potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT zhangna potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT maoyujie potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT huangbingbing potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT renmengfei potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT pengzhangjie potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT baizipeng potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT chenlong potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT liuyan potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT wangshanshan potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT huangshenghai potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients
AT chengzhixiang potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients